Is Brukinsa (Zanubrutinib) a Safer Bruton’s Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis

<b>Background/Objectives:</b> Zanubrutinib (Brukinsa) is a next-generation Bruton’s tyrosine kinase inhibitor approved for the treatment of relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); however, a comprehensive quantitative assessment of its sa...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Helal F. Hetta, Ayman Salama, Turki A. Aljuaid, Yazan T. Mojmami, Riyadh S. Alotibi, Ahmed M. Alqabaly, Nawaf A. Aldosari, Sami A. Alshahri, Walid I. A. Asiri, Raed S. Alamri, Fayez A. Alanazi, Malek S. A. Alenazi, Mohammed H. Albuhayri, Yasmin N. Ramadan, Reem Sayad
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2026-03-01
Saila:	Pharmaceuticals
Gaiak:	zanubrutinib BGB-3111 Bruton’s tyrosine kinase inhibitor chronic lymphocytic leukemia Brukinsa small lymphocytic lymphoma
Sarrera elektronikoa:	https://www.mdpi.com/1424-8247/19/3/467
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!